ENRUHE
PF-Atlas › Clinical Trials › NCT04099407

Pirfenidone and Advanced Liver Fibrosis.

Pirfenidone · Phase 2

Registry ID
NCT04099407
Phase
Phase 2
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
Start
2019-08-01

About this trial

Pirfenidone is evaluated in NCT04099407, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Grupo Mexicano para el Estudios de las Enfermedades Hepaticas. Current status: Completed.

View NCT04099407 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT04099407 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.